Skip to content
Open access

Genomic and transcriptomic quality control for an autologous iPSC-derived cell therapy for Parkinson's disease.

Sep 2026 · Cell Stem Cell · 0 citations · 61 references
Medicine

TL;DR

Preclinical manufacturing strategy and results demonstrating efficacy in a PD rodent model and safety in a 9-month GLP toxicology study are reported.

Abstract

Toward development of an autologous, induced pluripotent stem cell (iPSC)-based cell therapy for Parkinson's disease (PD), we demonstrate successful, reproducible genomic and transcriptomic qualification of patient-derived dopaminergic neuron precursor cells (DANPCs) across multiple donors. Our analysis includes whole-genome sequencing data from fibroblasts, iPSCs, and DANPCs and the development of NeuriTest, an RNAseq-based bioinformatic analysis of DANPCs designed to predict cell quality based on empirical animal data. Autologous cell therapies are immune matched to the patient, potentially augmenting durability of benefit compared to allogeneic cells while negating the need for immunosuppression and accompanying side effects. Patient-specific iPSCs are an autologous cell source that can be differentiated to dopaminergic neurons, the cell type lost in PD. We report here our preclinical manufacturing strategy and results demonstrating efficacy in a PD rodent model and safety in a 9-month GLP toxicology study.

Read PDF

Similar papers

Review Open access Oct 2026

From patient cells to patient therapy: Twenty years of iPSC-based translation in neurodegenerative disease

It is proposed that the interval between cell transplantation and long-term engraftment constitutes a biological “black box” in which graft fate and therapeutic outcome are determined, marking a conceptual transition from stem cell biology toward transplantation biology.

Y. Cha, Kwang-Soo Kim · 0 citations
Review Aug 2026

Induced pluripotent stem cells from discovery to translation

This Review evaluates the technological and translational trajectories that have defined the iPSC era and analyzes the operational barriers to therapeutic development, envisioning a paradigm shift in which iPSC-derived interventions transition from bespoke experimental models toward standardized, engineered biological...

Jaecheol Lee, Todd J. Herron, L. Studer et al. · 0 citations
Open access Sep 2026

A Patient-Derived iPSC-Based Model Reveals Neural Lineage-Specific Transcription of Endogenous HHV-6B

This patient-derived iPSC-based model provides a platform for investigating the biological significance of neural lineage-specific eHHV-6 transcripts and may facilitate interpretation of HHV-6 DNA detection in patients with eHHV-6 by enabling studies of cell type-dependent viral transcription.

Hiroki Miura, Tomoki Inagaki, T. Ohye et al. · 0 citations
Review Open access Aug 2026

The evolution of iPSC-based cell therapy across autologous and allogeneic pathways.

This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies as autologous and allogeneic iPSC therapies complement each other for distinct clinical demands.

Anmin Wang, Yunpei Zhang, Hong-Kui Deng et al. · 0 citations
Open access Aug 2026

Beyond animal models: using human pluripotent stem cell-derived stem and progenitor cells to predict cytotoxicity in normal tissues

Background The clinical efficacy of anticancer drugs is often limited by dose-dependent toxicity to normal cells, particularly to rapidly dividing stem and progenitor cell populations. Traditional preclinical toxicity screening relies on animal models or primary human cells/immortalized lines, both of which have signif...

K. Vincze, N. Varga, Szilárd Tóth et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.